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Abstract
Background: Tinnitus, the perception of sound and noise in absence of an auditory stimulus, has
been shown to be associated with maladaptive neuronal reorganization and increased activity of
the temporoparietal cortex. Transient modulation of tinnitus by repetitive transcranial magnetic
stimulation (rTMS) indicated that these areas are critically involved in the pathophysiology of
tinnitus and suggested new treatment strategies. However, the therapeutic efficacy of rTMS in
tinnitus is still unclear, individual response is variable, and the optimal stimulation area disputable.
Recently, continuous theta burst stimulation (cTBS) has been put forward as an effective rTMS
protocol for the reduction of pathologically enhanced cortical excitability.
Methods: 48 patients with chronic subjective tinnitus will be included in this randomized, placebo
controlled, three-arm trial. The treatment consists of two trains of cTBS applied bilaterally to the
secondary auditory cortex, the temporoparietal associaction cortex, or to the lower occiput (sham
condition) every working day for four weeks. Primary outcome measure is the change of tinnitus
distress as quantified by the Tinnitus Questionnaire (TQ). Secondary outcome measures are
tinnitus loudness and annoyance as well as tinnitus change during and after treatment. Audiologic
and speech audiometric measurements will be performed to assess potential side effects. The aim
of the present trail is to investigate effectiveness and safety of a four weeks cTBS treatment on
chronic tinnitus and to compare two areas of stimulation. The results will contribute to clarify the
therapeutic capacity of rTMS in tinnitus.
Trial registration: The trial was registered with the clinical trials register of http://
www.clinicaltrials.gov (NCT00518024).
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Background
Tinnitus
Tinnitus is the perception of sounds or noise in the
absence of an external stimulus. About 10 to 15% of the
general population [1] report this auditory phantom per-
ception [2]. Around 1 to 2% of the patients are seriously
impaired [1]. Sleep disturbances, depression, irritability,
and anxiety symptoms are the most common psychiatric
comorbidities of tinnitus [1,3]. Current therapies focus on
the "management of tinnitus", i. e. they are a means to
reduce tinnitus perception or awareness, and treating
comorbidities rather than curing tinnitus itself [4-6]. Cog-
nitive-behavioural therapies yield some relief [7], but are
often not sufficient. To date, there is no pharmacological
intervention or device available that has been proven to
reliably reduce tinnitus. The pathophysiological causes of
tinnitus are poorly understood which impedes the devel-
opment of rational and evidence based therapies. How-
ever, recent findings indicate that chronic tinnitus is the
result of maladaptive reorganization in the central audi-
tory system [8] that can be reflected in hyperacitivity of
cortical areas involved in the perception and processing of
auditory information [6,9-14].
Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) is a non invasive
method to depolarize cortical neurons based on the prin-
ciple of electromagnetic induction [15]. Applying series of
rapid consecutive single stimuli is called repetitive TMS
(rTMS). Low frequency rTMS (1 Hz) has been shown to
decrease the excitability of the motor cortex [16], whereas
high frequency rTMS (≥ 5 Hz) produces the opposite
effect [17]. rTMS causes activity changes in regions inter-
connected with the stimulated area through mono- or
polysynaptic connections [18], modulates subcortical
transmitter concentrations [19], and was shown to induce
morphological modifications in stimulated areas as well
as in areas linked to them [20]. Based on these findings,
rTMS is used experimentally to treat a wide range of clini-
cal disorders that may involve altered states of cortical
excitability [21], such as major depression [22,23], audi-
tory hallucinations [24], and stroke [25].
TMS and tinnitus
Repetitive transcranial magnetic stimulation has recently
been adopted to strengthen the concept of focally
increased cortical excitability as a pathophysiological
mechanism of tinnitus perception. Initially, it was shown
that a high-frequency (10 Hz) rTMS induced 'virtual'
lesion of temporoparietal cortical areas can transiently
reduce tinnitus [26,27]. Further studies indicated that the
effect size was negatively correlated with the tinnitus dura-
tion [28,29]. On the basis of these data, it has been pro-
posed that a rTMS-induced reduction of hyperactivity of
these cortical areas could yield beneficial effects for
patients with chronic tinnitus [27]. To test this notion,
low frequency rTMS was applied to areas of the tempo-
roparietal cortex showing tinnitus-related hyperacitivity.
Immediately after this intervention, tinnitus loudness was
reduced for up to 30 min. The degree of reduction was
dose dependent, and negatively correlated with tinnitus
duration [11]. Several small clinical studies indicate that
repeated application of low-frequency rTMS up to 2 weeks
may have lasting ameliorating effects on chronic tinnitus
[30-37]. However, the effect size was mostly moderate
and interindividual responses as well as effect duration
were highly variable. Further studies are needed to assess
the clinical relevance of rTMS treatment in tinnitus and to
identify the optimal stimulation paradigms as well as the
most effective stimulation target site. Recently, continu-
ous theta burst stimulation (cTBS) has been put forward
as a modified rTMS paradigm [38] that reduces cortical
excitability by applying three pulses at 50 Hz repeated
every 200 ms over 40 s [38,39] at an intensity of 80%
active motor threshold (AMT). For clinical purposes cTBS
appears to be an applicable technique due to its low inten-
sity, short duration, and similar efficacy [40]. In a first case
report we demonstrated that cTBS is an effective approach
to treat tinnitus [41].
Objectives
We hypothesize that compared to sham stimulation cTBS
can induce a distinctive attenuation of tinnitus distress
and loudness and thus be of therapeutic value. Further
aims of the study are:
￿ To compare the effect of cTBS on the secondary audi-
tory cortex with its effect on the temporoparietal asso-
ciation cortex.
￿ Assessment of safety in terms of impairment in audi-
ologic and speech-audiometric measures as well as the
documentation of other unwanted side effects.
Design and Methods
This randomised, placebo controlled study consists of 3
arms in a parallel design (Figure 1). Tinnitus distress,
loudness and annoyance will be assessed before, during,
and after 4 weeks of bilateral cTBS. Forty-eight patients
will be randomised in an 1:1:1 ratio to either cTBS over
the secondary auditory cortex (SAC), the temporoparietal
association cortex (TAC) or sham stimulation (placebo:
PLC).
Population
The patient population will consist of patients with a wide
middle range of tinnitus duration and excluding those
with an increased risk for adverse effect of TBS.Trials 2009, 10:74 http://www.trialsjournal.com/content/10/1/74
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Inclusion criteria
￿ Written informed consent
￿ Age: between 18 and 75 years
￿ Chronic tinnitus since at least 6 month, but not
more than 5 years.
Exclusion criteria
￿ Objective tinnitus
￿ Acute or chronic inflammation of the middle ear,
acute hearing loss, hearing loss due to an acoustic
trauma within less than past 6 weeks
￿ Morbus Menière or fluctuating hearing loss
￿ Epilepsy
￿ Brain trauma
￿ Brain surgery
￿ Heart pacemaker
￿ Intake of anticonvulsants, antipsychotics, and regu-
lar intake of benzodiazepin
￿ Suicidality
￿ Other severe pathological chronic condition that
might confound treatment effects or interpretation of
data
￿ Pregnancy
￿ Participation in another clinical study regarding tin-
nitus within the past 3 months and during enrolment
in our study.
Data sets
For evaluation of security all data gathered will be used
and analyzed as treated. The analysis of the efficacy meas-
ures, especially with respect to the stimulus placement,
requires a concentration on patients treated per protocol
(PP). Missing observations are imputed using a full condi-
tional Markov-Chain Monte Carlo method for variables
with more than 75% valid values. An exploratory analysis
of all dependent variables by the randomised treatment, i.
e. the mere intention to treat (ITT), will be conducted to
plan subsequent confirmatory studies.
Screening
Patients will be recruited via announcement in the local
press, the tinnitus outpatient clinic at the Department of
Psychiatry and Psychotherapy, and the outpatient clinic of
the Department of Otorhinolaryngology of the University
Hospital of Tübingen. A psychiatrist and an otolaryngolo-
gist will assess the eligibility according to the inclusion
and exclusion criteria listed above.
Baseline assessments
The detailed time course and plan of the study is displayed
in Table 1.
￿ Ear Nose and Throat (ENT) examination and audio-
logical assessment including
- Standard pure tone audiometry
- Speech audiometry in quiet (mono- and multi-
syllables, "Freiburger speech test")
- Hearing in noise test ("Oldenburger sentence
test") [42]
- Audiological tinnitus matching
￿ Structered Tinnitus Interview (STI) [43]
￿ Tinnitus Questionnaire (TQ) [44,45]
Study Design Figure 1
Study Design.Trials 2009, 10:74 http://www.trialsjournal.com/content/10/1/74
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￿ Visual Analogue Scales (VAS) for tinnitus loudness
and annoyance [46]
￿ Beck Depression Inventory (BDI) [47]
￿ Symptom checklist 90-revised (SCL-90R) [48].
Safety
Safety measures are pure tone and speech audiometry as
well as speech understanding in noise tests (at Baseline,
after 2 weeks of treatment and after the end of the treat-
ment). Adverse events are assessed daily and documented
according to the GCP guidelines. Safety and adverse
events will be reported together with the results. The
occurence of possible adverse effects will be reported in a
case report form and handled in compliance with GCP.
Study monitoring is provided by CenTrial (Tübingen, Ger-
many).
Outcome measures
The primary efficacy measure in the present study is the
change of the tinnitus distress as measured by the TQ [45]
after 4 weeks of cTBS. The TQ [45]), originally developed
by Hallam et al. [49], is the most widely used, well vali-
dated and reliable inventory [50] to quantify tinnitus
ditress available in German language [30,32,34,41,51-
58]. It comprises 52 multi-scaled items in order to assess
emotional and cognitive handicaps, penetrance of the tin-
nitus, hearing problems, sleep disturbances, and somatic
discomfort. The TQ was used in pharmacological, behav-
ioural and TMS studies. Pharmacological studies did not
yield therapeutic effects [58,59]. Behavioural therapy
yield effect sizes between 6 and 28% on the TQ [60,61].
Pilot rTMS studies reported effects sizes between 5 and
25% [34,41,52].
Table 1: Time course of the study
Investigation Screening Baseline Treatment Follow-Up
2 weeks 2 weeks 11 months
Visit # V0 V1 V2-10 V11 V12-20 V21 V22 V23 V24 V25 V26
informed consent ×
demograph. data ×
inclusion/exclusion criteria ×
randomization ×
ENT investigation/tinnitus localization ×
audiogram/speech audiometry × × ×
STI ×
cTBS treatment SAC, TAC, PLC × × × ×
documentation of side effects × × × ×
T Q × × x  * ×××××
VAS (distress, loudness) × × × × × × × × × ×
VAS (change) × ×
S C L - 9 0 R × × ××××××
B D I × × ××××××
*primary outcome measureTrials 2009, 10:74 http://www.trialsjournal.com/content/10/1/74
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Secondary efficacy variables are tinnitus change [46] and
the changes in BDI [47] and in the VAS for tinnitus loud-
ness and tinnitus annoyance [46,62].
Changes regarding psychopathology will be measured
using the SCL-90R [48]. Feasibility of the study will be
assessed and reported together with the results.
Follow-up assessments
Duration of treatment effects will be measured (TQ, VAS,
BDI) 6, 8, 16, 28, and 56 weeks after the first stimulation.
Furthermore, 6 months after the end of treatment patients
will be asked to report if they regard the estimated benefit
as worth the effort.
Withdrawal from the study
In case of endangerment of personal security or lack of
compliance or withdrawal of informed consent, a patient
will instantly be excluded from further participation in the
study.
Sample size calculation
Effect size and dispersion were taken from our last study
of TMS against tinnitus [34]. The ratios of tinnitus distress
score after treatment to tinnitus distress score at baseline
are assumed to follow normal distributions with standard
deviation 0.18 after taking logarithms. A relevant effect
size of 0.19 logarithmic units would arise from the ratio
of geometric mean scores of 80% of baseline after effica-
cious stimulation to 97% after sham stimulation. All three
pairwise group comparisons will be conducted. Therefore
the probabilities of the errors of first and second kind are
Bonferroni-adjusted to significance level 0.017 and power
0.93 locally to ensure multiple level 0.05 and multiple
power 0.8. Consequently the planned number of patients
to be included in the study is 48, i. e. 16 in each arm. A
closed testing procedure preserves the multiple signifi-
cance level and power while treatments are compared at
different points in time.
Data analysis
The geometric mean tinnitus score (TQ) in percent base-
line will be compared between the three groups after the
full treatment course of 4 weeks after the first stimulation,
after 6 weeks, as well as 28 and 56 weeks after the first
cTBS treatment in that prespecified order, as we expect
effects sizes to have that order. If one group comparison is
not statistically significant, the following comparisons are
rated as not significant too. The confidence intervals for
ratios of geometric means of tinnitus scores at 4 and 6
weeks will be computed from an analysis of variance
(ANOVA) with factors group (SAC, TAC, PLC) and time (4
and 6 weeks) and the group*time  interaction. Further
ANOVAs of TQ with the between subject factor group will
be carried out after 8, 28, and 56 weeks after the first treat-
ment. Their residual variances are expected to differ. The
longitudinal course of the stimulation effect will be
described using all TQ measurements, including measure-
ments at 2 and 16 weeks. Secondary efficacy measures will
be analysed similarly. Only the tinnitus change cannot be
divided by a baseline value and will be analysed by ordi-
nal logistic regression as it is ordinal. The daily measure-
ments on visual analog scales will be shown in diagrams.
Confidence interval computations will assume normality
of logit-transformed VAS. The routinely sampled safety
data will all be plotted for each patient and will be used to
quantify intensity and duration of adverse effects should
such occur. Data analysis will be performed in the Depart-
ment of Medical Biometry of University Hospital of
Tübingen using JMP 7.0 (SAS Institute Inc.) after imputa-
tion with SPSS 17.0 (SPSS Inc.).
Randomization
A randomisation list was prepared by the Department of
Medical Biometry of University Hospital of Tübingen
(RV) using permuted blocks. Allocations were concealed
in opaque sealed envelopes, that are opened by a third
person immediately prior to the first treatment.
Treatment
After screening, written informed consent, physical ENT
examination and audiological assessments, patients will
be assigned to one of the real (SAC, TAC) or sham (PLC)
treatment groups. TMS will be applied using a Magstim
Super Rapid (The Magstim Company Ltd, Whitland, UK)
with a figure-eight coil (diameter of each winding: 70
mm, biphasic stimulus of 250 μs, peak magnetic field:
2T). The individual motor threshold (AMT) will be
assessed at the beginning of the first treatment session.
AMT is defined as minimum stimulation intensity
required to induce a motor evoked potential (MEP) of
more than 200 μV on at least 5 out of 10 trials from the
contralateral abductor pollicis brevis muscle (APB) while
maintaining a voluntary contraction of about 20% of
maximum [39]. Stimulation (cTBS) intensity is 80% AMT
and will be applied to each side for 40 s in alternating
order. Fifteen minutes after the first two trains, a second
pair of cTBS will be applied (a total of 2400 stimuli per
day). Patients receive cTBS treatment each working day for
4 weeks.
Blinding
The endpoint assessor remains masked to the treatment
until the final data analysis. For adequate masking of the
patients, sham stimulations will be performed at the
lower occiput in the same distance to the ear [11,27,63].
In this way, the control stimulation is accompanied by a
similar noise (between 60 and 75 dB) and comparable
aversive sensation (pricking, muscle twitches).Trials 2009, 10:74 http://www.trialsjournal.com/content/10/1/74
Page 6 of 8
(page number not for citation purposes)
Data Management
Data are collected on paper case report forms that are
stored in a safe place until 10 years after completion of the
trial. Data are entered directly in the statistical analysis
software file on a safely kept computer with individual
user passwords. This process is replicated by a second per-
son and the resulting files are compared regularly, so that
ambiguous entries can be questioned in short time. Plau-
sibility checks, source data verification and quality control
are carried out by an external monitor.
Ethics, Consent, Study Organization and Registration
The trial will be conducted in agreement with the princi-
ples of the Declaration of Helsinki, and with the guidlines
of Good Clinical Practice (GCP) of the International Con-
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH).
The protocol was approved of by the local Indpendent
Ethics Committee (Institutional Review Board). Funding
is provided by the German Research Council. The investi-
gator will explain the benefits and risks of participation in
the study to each subject and will provide an informed
consent form approved by the independent ethics com-
mittee. Only patients, who sign the form, will be included
in the study. Results will be published so that patients can-
not be identified. All eligible patients are seen by a psychi-
atrist and an otolaryngologist and are enrolled after giving
informed consent. All findings will be recorded in the
patients' medical records and the CRF provided for this
study. Study auditing, CRF compilation and study moni-
toring is performed by CenTrial GmbH (Tübingen, Ger-
many).
Discussion
The available data on the efficacy of tinnitus treatment
with rTMS is incomplete [30-37]. The effect size, the clin-
ical relevance and the optimal stimulation parameters are
virtually unknown. This placebo-controlled phase II clin-
ical trial has been designed to investigate the efficacy of a
4 weeks treatment with bilateral cTBS on chronic tinnitus
and to compare the effectiveness of two different stimula-
tion areas. Since the laterality of tinnitus-related cortical
hyperactivity and rTMS effects in mono- and bilateral tin-
nitus have been shown to be interindividually variable
[11,64], we opted for a bilateral cTBS. Recent studies on
therapeutic efficacy of rTMS in major depression pointing
towards a superior effectiveness of longer treatment dura-
tions [23] prompted us to extend cTBS treatment to 4
weeks. Moreover, against the background of a dose
dependency of rTMS effects in tinnitus [11] and in order
to assure a sufficient dose of stimulation, the patients will
receive two stimulation trains on each side. Hence, bilat-
eral, long-term application of cTBS to two different corti-
cal sites will provide comprehensive data for an
evaluation of the clinical relevance of TMS treatment in
chronic tinnitus and an improvement of treatment
parameters. Based on the effect size and standard devia-
tion of the Intention-to-Treat analysis as well as on the
finding of the optimal stimulation localization a larger
clinical efficacy study will be designed.
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